Impact of Amantadine on Traumatic Brain Injury

  • days left to enroll
  • participants needed
  • sponsor
    Damanhour University
Updated on 1 February 2021


The aim of this study is to evaluate whether the addition of amantadine to the management regimen of traumatic brain injury patients would have a favorable effect on recovery and neurological complications in association with prognosis biomarkers Interleukin-18 (IL-18), Neuron-specific enolase (NSE) and (Neurotensin).


Proposal Steps

  1. Approval will be obtained from Research Ethics Committee of Faculty of Pharmacy, Damanhour University.
  2. All participants agreed to take part in this clinical study and provide informed consent.
  3. Patients will be enrolled if they present with clinical signs of trauma, from Emergency department at Tanta University Hospital
  4. Complete physical, laboratory, radiological assessment will be done for all patients
  5. Serum samples will be collected for measuring the biomarkers.
  6. All enrolled 50 patients will be divided into two groups; Group I are patients who will receive amantadine as added on therapy. Group II are patients who will be managed with the standard regimen.
  7. All patients will be followed up during 6 weeks period.
  8. At the end of 6 weeks, prognosis biomarkers will be withdrawn.
  9. Statistical tests appropriate to the study design will be conducted to evaluate the significance of the results.
  10. Measuring outcome: The primary outcome is to compare the effect of adding amantadine on recovery rate and neurological complications in trauma patients.
  11. Results, conclusion, discussion and recommendations will be given.


  • 50 Patients will be randomized equally to the assigned study groups
  • Prognosis biomarkers (IL-18, NSE and Neurotensin) will be measured using ELISA
  • Conventional routine tests (including renal function tests) will be assessed
  • Patients will be evaluated clinically (such as Glasgow score) for recovery rate for neurological complications.

Condition Brain Injury
Treatment Placebo, Amantadine (100mg) as add on therapy.
Clinical Study IdentifierNCT04527289
SponsorDamanhour University
Last Modified on1 February 2021


Yes No Not Sure

Inclusion Criteria

Adult patients will be enrolled if they present with clinical signs of trauma
brain injury

Exclusion Criteria

Age lower than 18
Females with positive pregnancy test
Known congestive heart failure or ischemic heart disease
Any injury disturbs the examination (high cervical cord injury or locked-in syndrome, could be a source of bias)
Penetrating head trauma
Need for any operation (laparotomy or craniotomy)
Severe brain disease (For example CVA history or brain tumour)
Renal failure with GFR lower than 60 ml/min
Patients with unknown identity
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note